Demonstrations held at the ASA Anesthesiology 2015 Conference in
Masimo Booth 3437 -San Diego Convention Center on October 24-28, 2015
IRVINE, Calif.--(BUSINESS WIRE)--Oct. 22, 2015--
Masimo
(NASDAQ: MASI) and Atheer
announced today that they will unveil a prototype of the Root Iris
display App using the Atheer AiR (Augmented interactive Reality)
platform and AiR Glasses at the American Society of Anesthesiologists
(ASA) annual conference. Demonstrations will be held at Masimo’s Booth
3437 at the San Diego Convention Center on October 24-28, 2015. The
demonstrations will allow conference attendees to experience a prototype
display and touch-free interactions powered by the Atheer AiR Glasses
that, if cleared by the FDA, would provide clinicians with a novel
display and interaction experience. Attendees will be invited to provide
feedback on features, usability and requirements.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20151022005630/en/
“This is the future of information display and interaction,” said Joe
Kiani, Founder and CEO of Masimo. “What was once seen only in the movies
is now on the way to becoming a reality. When combined with our Root
Iris technology, AiR Glasses may in the future empower anesthesiologists
to visualize data from multiple information sources and interact with
the data using motion gestures while continuing to care for the patient.”
“We are delighted to partner with Masimo – one of the most innovative
medical technology companies in the world. Our AiR smart glasses
platform is known for its rich display as well as unique touch-free
interaction using gestures, voice and head motion. Now both our
companies are leveraging our strengths to develop a novel platform for
the medical community,” said Alberto Torres, CEO of Atheer.
Special demonstrations and interviews will be scheduled by appointment
for the media. To schedule a media demonstration and interview time,
please call 858-859-7001. To obtain a media pass for the Anesthesiology
2015 conference, please email pr@asahq.org
or call 847-268-9106.
@MasimoInnovates
| #Masimo | @Atheerlabs | #AiRGlasses
About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through-Motion and Low Perfusion™ pulse oximetry,
which has been shown in multiple studies to significantly reduce false
alarms and accurately monitor for true alarms. The benefits of Masimo
SET® have been proven in more than 100 independent and objective studies
and it is estimated to be used on more than 100 million patients in
leading hospitals and other healthcare settings around the world. In
2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition
to SpO2, pulse rate, and perfusion index (PI). Additional information
about Masimo and its products may be found at www.masimo.com.
About Atheer
Atheer is the pioneer of AiR™ (Augmented interactive Reality) computing
that is designed to enhance deskless professional productivity. The
award-winning Atheer AiR platform combines the power of immersive
augmented reality with intelligent gesture, voice and head-motion
interaction, all on a mobile, smart glasses platform. Wearing our
see-through AiR Glasses, you can view rich information critical to your
workflow, interact with the information naturally and collaborate with
your remote peers like never before – all while on the move, without the
need to hold any device. Leveraging the Atheer AiR platform, developers
and companies around the world are creating next generation enterprise
productivity applications and workflows to empower the 21st century
workforce. For more information, please visit http://www.atheerlabs.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including: total hemoglobin (SpHb®) contribute to positive
clinical outcomes and patient safety; risks related to our belief that
Masimo noninvasive medical breakthroughs provide cost-effective
solutions with comparable accuracy and unique advantages, including:
immediate and continuous results that enable earlier treatment without
causing invasive trauma in all patients and in every clinical situation;
as well as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151022005630/en/
Source: Masimo
Masimo
Media:
Irene Paigah, 858-859-7001
irenep@masimo.com
or
Atheer
Media:
Kirsten
Maynard, 415-350-4147
Kirsten.maynard@sparkpr.com